Product logins

Find logins to all Clarivate products below.


Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)

Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the first-line treatment, usually in combination with diuretics when fluid overload is present. The addition of a second- or third-line treatment is often needed to better manage the disease. Given the heavily genericized nature of the market, branded agents have had difficulty establishing a foothold. However, the use of Entresto (sacubitril / valsartan) and SGLT-2 inhibitors has grown steadily since their launch. This report provides important insight into how these agents are used in the management of HFrEF and how practices are evolving.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFrEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
  • How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of HFrEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key companies: Pfizer, Merck & Co., Novartis, GSK, AstraZeneca, Johnson & Johnson Innovative Medicine, Eli Lilly, Boehringer Ingelheim, Amgen

Key drugs: ACE inhibitors, ARBs, beta blockers, MRAs, diuretics, CCBs, nitrates, ivabradine, vericiguat, Entresto (sacubitril / valsartan), SGLT-2 inhibitors

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…